Q5121 HCPCS code: Injection, infliximab-axxq, biosimilar, (avsola), 10 mg
Q5121 is the HCPCS Level II code for injection, infliximab-axxq, biosimilar, (avsola), 10 mg. In 2024 Medicare paid an average of $17.13 per service for Q5121 across 204,994 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 150 per day on outpatient hospital claims. Medicare volume fell 11% from 2022 to 2024 (230,240 to 204,994 services). In 2024, about 1,007 clinicians billed Medicare for Q5121 for 1,128 beneficiaries; Minnesota, North Carolina, Maryland accounted for 42% of services.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2020-07-01 |
| Last action effective | 2023-10-01 |
Who bills Q5121 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 1,007 |
| Medicare beneficiaries | 1,128 |
| States with claims | 26 |
| Share of services in top 3 states (Minnesota, North Carolina, Maryland) | 42% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for Q5121, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 230,240 | 1,134 | $38.58 | $30.66 |
| 2023 | 316,705 | 1,536 | $26.94 | $21.32 |
| 2024 | 204,994 | 1,128 | $21.75 | $17.13 |
States with the most Q5121 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Minnesota | 36,713 | $17.77 |
| North Carolina | 23,335 | $17.09 |
| Maryland | 19,881 | $17.50 |
| Colorado | 15,899 | $18.12 |
| Arizona | 10,951 | $18.14 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 150 | Prescribing Information |
| practitioner claims | 150 | Prescribing Information |
Medicare policy articles for this code
- A52423: Billing and Coding: Infliximab and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B))
- A56432: Billing and Coding: Infliximab (Palmetto GBA (MAC - Part A, MAC - Part B))
Covered diagnoses (692 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| D86.0 | Sarcoidosis of lung | 2 |
| D86.1 | Sarcoidosis of lymph nodes | 2 |
| D86.2 | Sarcoidosis of lung with sarcoidosis of lymph nodes | 2 |
| D86.3 | Sarcoidosis of skin | 2 |
| D86.81 | Sarcoid meningitis | 2 |
| D86.82 | Multiple cranial nerve palsies in sarcoidosis | 2 |
| D86.83 | Sarcoid iridocyclitis | 2 |
| D86.84 | Sarcoid pyelonephritis | 2 |
| D86.85 | Sarcoid myocarditis | 2 |
| D86.86 | Sarcoid arthropathy | 2 |
Showing 10 of 692. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for Q5121
- 2020-07-01: Q5121 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q5121?
Q5121 is the HCPCS Level II code for injection, infliximab-axxq, biosimilar, (avsola), 10 mg. Short descriptor: "Inj. avsola, 10 mg".
How much does Medicare pay for Q5121?
In 2024, the average Medicare payment was $17.13 per service (average allowed $21.75).
Does Medicare cover Q5121?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for Q5121?
Medicare policy articles that cite Q5121 list 692 covered ICD-10-CM diagnosis codes across 2 articles. The most cited include D86.0 (Sarcoidosis of lung), D86.1 (Sarcoidosis of lymph nodes), D86.2 (Sarcoidosis of lung with sarcoidosis of lymph nodes). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of Q5121 can be billed per day?
150 on outpatient hospital claims; 150 on practitioner claims (NCCI medically unlikely edits).
Related Q51 codes
- Q5100 — Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg
- Q5101 — Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
- Q5102 — Injection, infliximab, biosimilar, 10 mg
- Q5103 — Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
- Q5104 — Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
- Q5105 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
- Q5106 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5107 — Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
- Q5108 — Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5109 — Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
- Q5110 — Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5111 — Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q5121
- Watch Q5121 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q5121
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.